115 related articles for article (PubMed ID: 2154920)
41. Needle-localized biopsy of occult breast lesions: an update.
Snell MJ; Ostrow LB; DuBois JJ; Boyle LM; Calfee LW
Mil Med; 1992 Feb; 157(2):61-4. PubMed ID: 1318524
[TBL] [Abstract][Full Text] [Related]
42. Screening ultrasonography revealed 15% of mammographically occult breast cancers.
Uchida K; Yamashita A; Kawase K; Kamiya K
Breast Cancer; 2008; 15(2):165-8. PubMed ID: 18224382
[TBL] [Abstract][Full Text] [Related]
43. Is there still a role for fine-needle aspiration cytology in breast cancer screening? Experience of the Verona Mammographic Breast Cancer Screening Program with real-time integrated radiopathologic activity (1999-2004).
Manfrin E; Mariotto R; Remo A; Reghellin D; Dalfior D; Falsirollo F; Bonetti F
Cancer; 2008 Apr; 114(2):74-82. PubMed ID: 18306357
[No Abstract] [Full Text] [Related]
44. [Clinically impalpable mammary carcinoma: morphologic and histogenetic analysis. Apropos of 114 cases].
Meynard P; Jacquemier J; Hans D; Ayme Y; Varette Y; Spitalier JM; Amalric R; Hassoun J
Bull Cancer; 1989; 76(6):653-63. PubMed ID: 2550103
[TBL] [Abstract][Full Text] [Related]
45. Detection of localized breast cancer by prospective mammographic screening criteria.
Knaus JV; Dolan JR; Isaacs JH
Am J Obstet Gynecol; 1988 Jan; 158(1):147-9. PubMed ID: 2827485
[TBL] [Abstract][Full Text] [Related]
46. Progression of mammary adenocarcinomas as reflected by nuclear DNA content.
Auer GU; Fallenius AG; Erhardt KY; Sundelin BS
Cytometry; 1984 Jul; 5(4):420-5. PubMed ID: 6468180
[TBL] [Abstract][Full Text] [Related]
47. The content of tumor DNA as an indicator of prognosis in patients with T1N0M0 and T2N0M0 carcinoma of the breast.
Ellis CN; Frey ES; Burnette JJ; Akin JM; Reading C; Gaskin TA; Blakemore WS
Surgery; 1989 Aug; 106(2):133-8. PubMed ID: 2763022
[TBL] [Abstract][Full Text] [Related]
48. Atypical ductal hyperplasia: improved accuracy with the 11-gauge vacuum-assisted versus the 14-gauge core biopsy needle.
Sohn V; Arthurs Z; Herbert G; Keylock J; Perry J; Eckert M; Fellabaum D; Smith D; Brown T
Ann Surg Oncol; 2007 Sep; 14(9):2497-501. PubMed ID: 17564749
[TBL] [Abstract][Full Text] [Related]
49. Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammography.
Weaver DL; Rosenberg RD; Barlow WE; Ichikawa L; Carney PA; Kerlikowske K; Buist DS; Geller BM; Key CR; Maygarden SJ; Ballard-Barbash R
Cancer; 2006 Feb; 106(4):732-42. PubMed ID: 16411214
[TBL] [Abstract][Full Text] [Related]
50. Nonpalpable breast cancer: needle-localized biopsy for diagnosis and considerations for treatment.
Marrujo G; Jolly PC; Hall MH
Am J Surg; 1986 May; 151(5):599-602. PubMed ID: 3010754
[TBL] [Abstract][Full Text] [Related]
51. DNA distributions in human normal, precancerous and cancerous breast tissue. I. Ploidy and cell cycle distribution.
Weiss H; Kunde D; Streller B
Arch Geschwulstforsch; 1986; 56(5):373-9. PubMed ID: 3021084
[TBL] [Abstract][Full Text] [Related]
52. Scintimammographic analysis of nonpalpable breast lesions previously identified by conventional mammography.
Tolmos J; Cutrone JA; Wang B; Vargas HI; Stuntz M; Mishkin FS; Diggles LE; Venegas RJ; Klein SR; Khalkhali I
J Natl Cancer Inst; 1998 Jun; 90(11):846-9. PubMed ID: 9625173
[TBL] [Abstract][Full Text] [Related]
53. Nuclear DNA content and behavior of oxyphil thyroid tumors.
Bondeson L; Azavedo E; Bondeson AG; Caspersson T; Ljungberg O
Cancer; 1986 Aug; 58(3):672-5. PubMed ID: 2425922
[TBL] [Abstract][Full Text] [Related]
54. Mammography and the primary care management of breast lumps.
Banerjee A; Burke M
Practitioner; 1989 May; 233(1468):652-5. PubMed ID: 2557602
[TBL] [Abstract][Full Text] [Related]
55. Computed tomographic mammography. Diagnosis of mammographically and clinically occult carcinoma of the breast.
Sibala JL; Chang CH; Lin F; Jewell WR
Arch Surg; 1981 Jan; 116(1):114-7. PubMed ID: 6258536
[TBL] [Abstract][Full Text] [Related]
56. [Grading, staging, DNA content and prognosis of invasive ductal breast cancer].
Theissig F; Kunze KD; Haroske G; Meyer W; Dimmer V
Zentralbl Chir; 1990; 115(7):433-9. PubMed ID: 2164288
[TBL] [Abstract][Full Text] [Related]
57. Comparison between histologic type, estrogen receptor, and nuclear DNA content in mammary carcinoma.
Erhardt K; Auer G; Folin A; Silfverswärd C; Skoog L
Am J Clin Oncol; 1986 Feb; 9(1):83-9. PubMed ID: 3006475
[TBL] [Abstract][Full Text] [Related]
58. [Nonpalpable lesions of the breast. Diagnostic and therapeutic considerations].
Bellantone R; Rossi S; Lombardi CP; De Fazio S; Agresti M; Pastore G; Crucitti F
Minerva Chir; 1994 Apr; 49(4):327-33. PubMed ID: 8072710
[TBL] [Abstract][Full Text] [Related]
59. Nonpalpable breast cancer.
Bunnell DH; Bassett LW; Eggerding F; Steckel R
Am Fam Physician; 1987 May; 35(5):147-51. PubMed ID: 3034014
[TBL] [Abstract][Full Text] [Related]
60. Is stereotactic large-core needle biopsy beneficial prior to surgical treatment in BI-RADS 5 lesions?
Hoorntje LE; Peeters PH; Mali WP; Borel Rinkes IH
Breast Cancer Res Treat; 2004 Jul; 86(2):165-70. PubMed ID: 15319568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
